Key Developments: Pfizer Inc (PFE)

PFE on New York Consolidated

32.22USD
31 Aug 2015
Change (% chg)

$-0.44 (-1.35%)
Prev Close
$32.66
Open
$32.71
Day's High
$32.72
Day's Low
$31.96
Volume
32,034,626
Avg. Vol
23,808,424
52-wk High
$36.46
52-wk Low
$27.51

Search Stocks

Latest Key Developments (Source: Significant Developments)

Alvogen to acquire product portfolio from Pfizer for the U.S. Market
Wednesday, 26 Aug 2015 06:12am EDT 

Pfizer Inc:Alvogen has entered into a definitive agreement with Pfizer Inc, under which it will acquire a portfolio of four pharmaceutical products in the U.S.Acquired portfolio includes four products that are being divested by Pfizer as a precondition to its closing of the acquisition of Hospira.In addition, Alvogen will acquire two pending ANDA's, Voriconazole injection and Melphalan injection.Both pending applications represent generic market with limited participation and are expected to launch as early as 2016.  Full Article

Pfizer Inc receives clearance from U.S. Federal Trade Commission for Hospira acquisition
Monday, 24 Aug 2015 08:00am EDT 

Pfizer Inc:Receives clearance from U.S. federal trade commission for Hospira acquisition.Says transaction expected to close in early Sept. 2015.Says FTC consent order includes agreement to divest four sterile injectable assets.Says Brazil's superintendency-general of cade has published its unconditional clearance decision.  Full Article

Pfizer announces positive topline results of two phase 3 studies of Trumenba
Friday, 21 Aug 2015 08:00am EDT 

Pfizer Inc:Announces positive topline results of two Phase 3 studies of TRUMENBA((reg))(Meningococcal Group B Vaccine).Says one study included about 3,600 healthy individuals 10 through 18 years of age, and the other study included about 3,300 healthy individuals 18 through 25 years of age.  Full Article

Pfizer Inc gets Canadian Competition Bureau approval for Hospira acquisition
Friday, 14 Aug 2015 08:35am EDT 

Pfizer Inc:Granted approval from the Canadian Competition Bureau with respect to its pending acquisition of Hospira.As part of its agreement with the Canadian Competition Bureau, Pfizer has committed to divest certain assets in Canada.  Full Article

Gliknik licensee Pfizer Inc receives orphan drug designation from U.S.FDA for drug candidate directed towards rare neurological disorder
Monday, 10 Aug 2015 08:00am EDT 

Pfizer Inc:Gliknik licensee Pfizer receives orphan drug designation from U.S. food and drug administration for drug candidate directed towards rare neurological disorder.Gliknik inc says gl-2045 received orphan drug designation for cidp following a review by the FDA of a package of data submitted by Pfizer.GL-2045 received Orphan Drug designation for CIDP under the U.S. Orphan Drug Act following a review by the FDA of a package of data submitted by Pfizer.Says FDA Office of Orphan Products Development grants orphan drug designation to novel drugs or biologics that treat a disease or condition affecting fewer than 200,000 patients in U.S.  Full Article

Pfizer and synthon enter into U.S. commercialization agreement for potential generic treatment of multiple sclerosis
Monday, 3 Aug 2015 08:30am EDT 

Pfizer:Pfizer and synthon enter into U.S. commercialization agreement for potential generic treatment of multiple sclerosis.Says Pfizer will have exclusive rights to commercialize both dosage formulations of synthon's glatiramer acetate in the United States.Says Pfizer is solely responsible for the commercialization of glatiramer acetate in the United States.Says financial terms of the agreement were not disclosed.Says synthon is responsible for the clinical development, manufacture and supply of glatiramer acetate.  Full Article

Pfizer Inc raises low end of prior FY 2015 revenue guidance and raises FY 2015 EPS guidance
Tuesday, 28 Jul 2015 07:00am EDT 

Pfizer Inc:Expects FY 2015 reported revenues of $45.0 to $46.0 bln (previously $44.0 to $46.0 billion).Expects FY 2015 reported diluted EPS in the range of $1.38-$1.47 (previously $1.32 to $1.47).Expects FY 2015 adjusted diluted EPS in the range of $2.01-$2.07 (previously $1.95 to $2.05).FY 2015 revenue of $45.978 billion and EPS of $2.04 - Thomson Reuters I/B/E/S.  Full Article

Pfizer Inc Announces FDA acceptance for review of New Drug Application for a once-daily formulation of XELJANZ modified release tablets
Thursday, 2 Jul 2015 04:30pm EDT 

Pfizer Inc:Says the FDA has provided an anticipated prescription drug user fee act (PDUFA) action date in February 2016 for the NDA.  Full Article

Pfizer Inc declares 28-cent third-quarter 2015 dividend
Thursday, 25 Jun 2015 11:15am EDT 

Pfizer Inc:Declares 28-cent third-quarter 2015 dividend on the company's common stock.Payable Sept 2, to shareholders of record at the close of business on Aug. 7.  Full Article

Pfizer Inc to acquire Nimenrix And Mencevax from GlaxoSmithKline Plc
Monday, 22 Jun 2015 07:10am EDT 

Pfizer Inc:Enters into agreement to acquire Nimenrix And Mencevax from Glaxosmithkline Plc.Says deal valued at about $130 million.Pfizer's legal advisors for the transaction were Ropes & Gray and Clifford Chance.  Full Article

EU mergers and takeovers (Aug 18)

BRUSSELS, Aug 18 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

Search Stocks